Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN versus ILOTYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN versus ILOTYCIN.
ERYTHROMYCIN vs ILOTYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking the translocation step.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking peptidyl transferase activity and preventing translocation of peptides.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours; maximum 4 g/day.
Erythromycin base (Ilotycin): 250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day. For IV: 15-20 mg/kg/day continuous infusion or divided every 6 hours.
None Documented
None Documented
Terminal half-life is 1.4-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in anuria.
Clinical Note
moderateErythromycin + Norfloxacin
"Erythromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateErythromycin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Erythromycin."
Clinical Note
moderateErythromycin + Ibandronate
"Erythromycin may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateErythromycin + Indapamide
Terminal elimination half-life is 1.5-2 hours in adults, prolonged to 4-6 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Primarily hepatic (biliary) elimination; approximately 2-5% excreted unchanged in urine, 30-60% excreted in feces via bile.
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-15% biliary/fecal elimination.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic
"Erythromycin may increase the QTc-prolonging activities of Indapamide."